U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H15Cl3N2OS
Molecular Weight 437.77
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERTACONAZOLE

SMILES

ClC1=CC(Cl)=C(C=C1)C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl

InChI

InChIKey=JLGKQTAYUIMGRK-UHFFFAOYSA-N
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/ertaczo-drug.htm https://www.drugs.com/mtm/sertaconazole-topical.html http://www.wikidoc.org/index.php/Sertaconazole

Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ERTACZO

Approved Use

ERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section).

Launch Date

1.07101441E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.79 ng/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43.31 ng × h/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.25 h
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
SERTACONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 2 times / day steady, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: steady
Dose: 2 %, 2 times / day
Sources: Page: 6.1
healthy, adult
n = 202
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 202
Sources: Page: 6.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans.
1992 May
In vitro antifungal activity of sertaconazole.
1992 May
In vitro activity of sertaconazole.
1992 May
In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp.
1995 Oct
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
1996 Mar-Apr
Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes.
1997 Nov-Dec
Patents

Sample Use Guides

Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration: Topical
In Vitro Use Guide
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Name Type Language
SERTACONAZOLE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
Sertaconazole [WHO-DD]
Common Name English
sertaconazole [INN]
Common Name English
1-(2-((7-CHLOROBENZO(B)THIEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-1H-IMIDAZOLE
Systematic Name English
SERTACONAZOLE [MI]
Common Name English
FI-7045
Code English
SERTACONAZOLE [VANDF]
Common Name English
1H-IMIDAZOLE, 1-(2-((7-CHLOROBENZO(B)THIEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QD01AC14
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
NDF-RT N0000008217
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
NCI_THESAURUS C514
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
NDF-RT N0000175487
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
WHO-ATC D01AC14
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
WHO-ATC G01AF19
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
Code System Code Type Description
DRUG CENTRAL
2434
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
INN
6008
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
CHEBI
82866
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
CAS
99592-32-2
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
MESH
C061131
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
DAILYMED
72W71I16EG
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
WIKIPEDIA
SERTACONAZOLE
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
EPA CompTox
DTXSID0048551
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
PUBCHEM
65863
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
DRUG BANK
DB01153
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201196
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
RXCUI
36435
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY RxNorm
MERCK INDEX
m9874
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY Merck Index
SMS_ID
100000084320
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
EVMPD
SUB10497MIG
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
FDA UNII
72W71I16EG
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY
NCI_THESAURUS
C75206
Created by admin on Sat Dec 16 17:27:25 UTC 2023 , Edited by admin on Sat Dec 16 17:27:25 UTC 2023
PRIMARY